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Abstract
Laboratory-based diagnosis of infectious diseases is evolving quickly. New technologies and new tests are frequently commercialized,
and although guidelines for their proper clinical validation do exist, these are often at the national or regional level. Therefore, the
guidelines remain open to interpretation, and are not always applied properly. One of the main questions is how a high level of test
quality can be maintained by European legislation. How can product quality be reliably and independently assessed and how can the pen-
etration of sub-standard assays in the European market be managed and hopefully prevented? We here propose that local initiatives,
including external quality assessment, public health initiatives, and close multidisciplinary collaborations between manufacturers and aca-
demic research institutes, may accelerate decision-making. Vigilance in test quality assessment and legal simpliﬁcation are important key
concepts warranting selective use of those diagnostic tests that comply with the highest quality standards.
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Introduction
Fifty years ago, many of the infectious pathogens currently
described in humans were not even discovered. Agents such
as human immunodeﬁciency virus (HIV) and hepatitis C virus
(HCV) were unknown, as were several bacterial species [1–
4]. To date, the variety and complexity of in vitro diagnostic
(IVD) tests have expanded and evolved to such an extent
that these previously unknown pathogens can also be
detected and identiﬁed to an adequate taxonomic level.
Hence, IVD research has been dynamic and innovative [5,6].
The current tests are fast and timely, and provide informa-
tion beyond simple detection and determination. The
required clinical samples are smaller than was required in
the past, and many samples are taken with minimal trauma.
The current generation of tests is also increasingly user-
friendly. This has led to the availability of point-of-care (PoC)
and near-patient testing formats that are easy to use for
medical personnel and, in some cases, allow self-sampling [7].
Innovative (molecular) technologies, including next-genera-
tion sequencing, microelectronics and microﬂuidics, allow for
continuous miniaturization of tests, and DNA or protein
‘arrays’, ‘biochips’ or ‘lab-on-a-chip’ devices are going to be
(widely) used [8,9]. The application of nanotechnology will
further improve the quality and broad-spectrum applicability
of novel generations of IVD tests for infectious and other
diseases [10]. IVD testing should facilitate personalized medi-
cine, whereby diagnostics and therapy are directly coupled.
These ‘theranostic’ devices are currently being introduced
into clinical laboratories [11,12]. Within the framework of
this Theme Section, we will discuss the European governance
of quality clearance of such novel and innovative tests in the
domain of infectious diseases. This will highlight the general
regulatory aspects, mainly from a technology perspective, but
exempliﬁed by several viral and (atypical) bacterial business
cases.
Molecular IVD testing is the fastest-growing segment, with
an explosive growth of nucleic acid diagnostics for infectious
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diseases. These tests provide high economic value, both
commercially and medically. Their most prominent features
are sensitivity, speciﬁcity, timeliness, speed, and the fact that
they generate critical therapeutic information for the infec-
tious disease specialist when clinical intervention is still possi-
ble. To date, the initiation of antibiotic therapy or its
reﬁnement have increasingly depended on the outcome of a
molecular laboratory test [13]. It may be the molecular PoC
or rapid laboratory-based tests that have the greatest poten-
tial to facilitate clinical decision-making. Tests that play such
an important role will have to be subjected to rigorous qual-
ity control. This has led to the introduction of common reg-
ulatory requirements dealing with the safety, quality and
performance of IVD medical devices: EU Directive 98/79/EC,
describing the quality criteria and their management, was
published on 7 December 1998 [14]. The ﬁrst publication
initiated a transition period that ended on 7 December
2003. From that moment onwards, IVD devices placed on
the European market had to comply with the Directive. This
meant that only ‘Conformite´ Europe´ene’ (CE)-marked
devices could be offered to diagnostic laboratories. This
should ensure that only safe and functional products would
be placed on the European market and it should facilitate
the free ﬂow of goods, persons, services and capital in this
market segment.
Summary of EU Directive 98/79/EC
EU Directive 98/79/EC of the European Parliament applies to
IVD medical devices and their accessories. The following
technical deﬁnitions were applied:
1 ‘Medical device’ refers to any instrument, apparatus,
appliance, material, or other article, whether used alone
or in combination, including the software necessary for
its proper application, intended to be used for the pur-
pose of diagnosis, prevention, monitoring, treatment or
alleviation of human disease.
2 ‘In vitro diagnostic medical device’ refers to a reagent, a
reagent product, a calibrator, control material, a kit, an
instrument, apparatus, equipment, or a system, used
alone or in combination, intended to be used for the
examination of human specimens for the purpose of pro-
viding information concerning a physiological or patholog-
ical state, or concerning a congenital abnormality, for
determining the safety and compatibility with recipients,
or for monitoring therapeutic measures.
3 ‘Device for self-testing’ refers to any device to be used
by lay persons at home.
4 ‘Device for performance evaluation’ refers to any device
that will be subject to performance evaluation studies in
medical laboratories or in other environments.
5 ‘Manufacturer’ refers to the natural or legal entity with
responsibility for the design, manufacture, packaging and
labelling of a device.
6 ‘Authorized representative’ refers to any natural or legal
entity designated by the manufacturer who may be
addressed by authorities in the EU instead of the manu-
facturer with regard to the latter’s obligations.
7 ‘Intended purpose’ refers to the use for which the device
is intended
8 ‘Placing on the market’ refers to the ﬁrst availability in
return for payment or free-of-charge use of a device
other than when a device is distributed for performance
evaluation purposes only.
9 ‘Putting into service’ refers to the stage at which a device
has been made available to the ﬁnal user as being ready
for use.
For the purposes of EU Directive 98/79/EC, the collection of
human tissues, cells and substances shall be ethically gov-
erned by the Convention of the Council of Europe for the
protection of human rights and dignity. Member states will
not create obstacles to the placing on the market or the
putting into service within their territory of devices bearing
the CE marking if these devices have undergone conformity
assessment. Neither shall member states create obstacles to
devices intended for performance evaluation in the laborato-
ries using such tools.
Manufacturers are required to comply with the common
technical speciﬁcations (CTSs): if manufacturers do not com-
ply with those speciﬁcations, then they must adopt solutions
of an equivalent level. Where reference is made to harmo-
nized standards, this is also meant to refer to the CTSs.
During the conformity assessment procedure for a device,
the manufacturer shall take account of the results of any
assessment and veriﬁcation operations that have been car-
ried out at an intermediate state of manufacture.
Devices considered to meet the essential requirements
must bear the CE mark of conformity when they are placed
on the market. The CE mark shall be accompanied by the
identiﬁcation number of the notiﬁed body responsible for
implementation of the procedures [15].
The manufacturer must prepare technical documentation
to qualify for certiﬁcation of the IVD product, and ensure
that the manufacturing process follows the principles of
accepted quality assurance. The technical documentation
must allow assessment of the conformity of the product, and
it must include the following:
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1 A general description of the product and its intended use.
2 The documentation of the quality system.
3 Design information, including characteristics of the basic
materials, characteristics and limitation of the perfor-
mance of the devices, methods of manufacture, design
drawings, etc.
4 Information on the origin of human substances and on
collection conditions.
5 The descriptions and explanations necessary to under-
stand the operation of the product.
6 The results of the risk analysis, and a list of the stan-
dards and descriptions of the solutions adopted to meet
the essential requirements.
7 In the case of sterile products or products with a spe-
cial microbiological state or state of cleanliness, a
description of the procedures used.
8 The results of design calculations and inspections.
9 If the device is to be combined with other device(s),
proof that, in such combinations, it conforms to the
requirements.
10 The test reports.
11 Adequate performance evaluation data, showing the
performances claimed by the manufacturer with infor-
mation on the reference methods, the reference mate-
rials, the known reference values, the accuracy, and
measurement units used, all based on clinical studies or
clear bibliographies.
12 The labels and instructions for use.
13 The results of stability studies.
Only when these requirements are adequately met, either by
the notiﬁed body or, in the case of self-certiﬁcation, by the
manufacturer, can the certiﬁcation of the IVD proceed.
General Features of IVD Tools
An IVD medical device is deﬁned as a diagnostic system as
described above [16]. The results should deﬁne a physiologi-
cal or pathological state, possibly also in relation to a con-
genital abnormality. It should be useful in the application and
monitoring of therapeutic measures, and it should be of use
in the diagnosis, prognosis, therapy selection, immediate
therapy response assessment and longer-term therapy moni-
toring of human disease. Several features are not covered by
EU Directive 98/79/EC. These include some certiﬁed refer-
ence materials and internationally recognized standards, such
as those developed by collaborative studies under the direc-
tion of the WHO expert committee on biological standardi-
zation (e.g. WHO standards). Materials solely used for
external quality assessment (EQA) are also not covered
under article 9 of EU Directive 98/79/EC. In addition, equip-
ment dedicated to research purposes only is exempted, also
assuming that, in such applications, the equipment serves
purposes without immediate medical objectives. Home-made
tests that are used for medical purposes are usually subject
to national regulations. In these cases, accreditation to the
requirements of ISO 15189 (Medical Laboratories—Particu-
lar Requirements for Quality and Competence) provides a
regulatory alternative [17].
The key objective of EU Directive 98/79/EC is to ensure
that only safe and functional products are sold in the EU mar-
ket. It is aimed to provide patients with a high level of health
protection, and it should guarantee the safety, the safe use and
the performance of IVD test systems. The Directive provides
‘clear’ regulations on the manufacturing, importation and mar-
keting of IVDs; it is also helpful in unifying modes of notiﬁca-
tion of the IVD test by the manufacturer to the competent
authorities. This should ensure that veriﬁcation of conformity
by the assigned notiﬁed bodies is streamlined. The Directive
aids in technical harmonization: rules on the safety, quality and
performance of IVD tests should be highly transparent, and all
tests should adhere to the same speciﬁcations and require-
ments. Finally, it should facilitate excellent and efﬁcient com-
munication between all competent authorities involved.
Many IVD tests are covered by EU Directive 98/79/EC.
These include the tests identiﬁed in Annex II List A (blood
grouping, ABO, Rhesus (C, c, D, E, e), anti-Kell, blood virals,
HIV1 and HIV2, human T-lymphotropic virus I and II, hepati-
tis B, C, and D) and Annex II List B (irregular anti-erythrocyte
antibodies, congenital infections (rubella, Toxoplasma), heredi-
tary disease (phenylketonuria), blood grouping (anti-Duffy,
anti-Kidd), human infections (cytomegalovirus, Chlamydia),
HLA tissue groups (DR, A, B), tumour markers (prostate-spe-
ciﬁc antigen, trisomy 21), including software)), and the cate-
gory of self-tests, blood sugar tests, and ‘most other IVD tests’
[18]. This provides a descending ranking from List A to the
more generally applicable and less strict IVD tests. Not all of
these tests are subject to the same assessment: there is a vari-
ety of conformity assessment procedures related to various
classes of medical risks (for Annex II List A, CTSs detail
required performance evaluation criteria, re-evaluation of pro-
cesses such as sensitivity and speciﬁcity testing, etc.). For
instance, the high-risk IVD tests may require rather extensive
laboratory-based performance evaluations. The notiﬁed bodies
are only involved in the assessment of ‘higher-risk’ products,
and more than one possible assessment route for ‘higher-risk’
products is available. Interestingly, ‘self-certiﬁcation’ of IVD
tests considered to be ‘low risk’ is a distinct possibility, and
there is only limited review of tests for home use [19].
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In summary, the basic ingredients and quality suggestions
of EU Directive 98/79/EC are:
1 To provide a common presumption of conformity by
using generalized ‘European Harmonized Standards’,
although even the current, rather elaborately described,
IVD test guidelines are still open to different interpreta-
tions.
2 To provide a stable presumption of conformity by using
common technical CTSs for devices in Annex II List A
and, where necessary, in Annex II List B.
3 To facilitate premarket approval, although to date this
applies to only a limited number of IVD tests.
4 To facilitate the CE labelling of most new IVD tests by
their manufacturers, and provide conditions that make
most of the novel tests to be covered by the self-certiﬁ-
cation rule.
EU Directive 98/79/EC is intended to guarantee conformity
of IVD products as available on the European market. It
should facilitate greater harmony and traceability of such
products. The ultimate goal of such regulations is to pro-
mote the growth of international free markets with a clear
vision and guarantee of the quality of the products in these
markets. On the other hand, and speciﬁcally in the ﬁeld of
nucleic acid diagnostics, there are also disadvantages of such
regulations. For example, there will be potentially increased
regulatory pressures on the clinical laboratory and the many
in-house-developed or home brew nucleic acid tests may fall
under the Directive and may need a formal IVD test require-
ment [20]. In several cases, there has been a notable lack of
suitable reference materials to support the test development
in line with IVD requirements, and hence there may some-
times be difﬁculties in complying with the Directive.
Despite the implementation of the regulations, several
important questions remain. For instance, if the regulations
are coherent, then why do some diagnostic tests differ so
much in performance level? And the most important ques-
tion remaining is whether CE-marked tests always succeed in
outperforming their non-CE-marked counterparts.
Molecular Diagnostic Tools and
technological Platforms
A large number of molecular tests have been launched with
clinical success. These tests are diverse in nature and,
although PCR is generally considered to be the mainstay and
most frequently applied of the current molecular technolo-
gies, many other technologies have been introduced onto
the diagnostic market. These include hybrid capture assays,
nucleic acid sequence-based ampliﬁcation, and nucleic acid
probe-mediated tests (ﬂuorescence in situ hybridization) with
or without microscopy, ﬂuorescence-activated cell sorting
technology, direct ﬂuorescence measurement, etc.). This
wave of novel tests has led to improvements in the sensitiv-
ity and speciﬁcity of the detection of pathogens, and several
tests have successfully passed the scrupulous screening by
the US Food and Drug Administration [21]. It is estimated
that molecular diagnostics tests for infectious diseases com-
prise almost 70% of the entire market for molecular tests
[22]. The current top diagnostic targets are the human papil-
lomaviruses [23], Chlamydia trachomatis, and Neisseria gonor-
rhoeae, often in combination [24], HIV [25], herpes simplex
virus [26], and agents of hospital-acquired infections (methi-
cillin-resistant Staphylococcus aureus, Clostridium difﬁcile, vanco-
mycin-resistant enterococci, Enterobacteriaceae producing
extended-spectrum b-lactamases or Klebsiella pneumoniae
carbapenemase, and some others) [27]. Of course, molecular
tests are available for all clinically relevant microorganisms,
including major killers such as the malaria agent or Mycobac-
terium tuberculosis. The quality of these tests has recently
been redeﬁned by the US CLSI in document MM19, entitled
‘Establishing molecular testing in clinical laboratory environ-
ments’ [28]. In summary, over the past 25 years, molecular
testing has evolved: from the initial and simple staining-based
or ﬂuorescence-based tests, we now have formats in real
time, allowing precise and automated quantitation of molecu-
lar targets. Short turn-around times are combined with mini-
mal hands-on times, and some of these tests can even be
used in resource-poor environments [29,30].
Performance of Molecular Tests for the
Detection of Blood-borne Viruses belonging
to Annex II List A or B of Directive 98/79/
EC
The quality of tests can be assessed by external, independent
quality assessment. Such assessments have been developed
by the Quality Control of Molecular Diagnostics (QCMD)
organization [31–34]. The organization was established with
the help of a Framework Programme 4 EU research grant,
but is now completely self-supporting. The general aim of
the QCMD EQA programmes is to assess laboratory abilities
to detect and determine speciﬁc infectious disease pathogens
in the routine laboratory setting with molecular technologies.
This is done through the manufacturing, in large quantities or
numbers, of (mock) clinical specimens of identical composi-
tion and with variable pathogen densities. Such specimens
are to be distributed among clinical laboratories for
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decentralized comparative testing. Fig. 1 explains the QCMD
scoring system for quantitative EQA data [35]. Fig. 1b shows
combined results obtained during molecular proﬁciency test-
ing for cytomegalovirus, hepatitis B virus, HCV, Epstein–Barr
virus and HIV from 2007 to 2010, both for commercially
available tests and for in-house-developed tests. The data
show a tendency towards better performance of most tests
and laboratories over the years, and it is suggested that com-
mercial tests perform a little better than in-house-developed
tests (lower numbers of scores of 2 (±3 standard deviations)
and 3 (>3 standard deviations). Fig. 2 shows the results of
comparative analysis of commercial and in-house assays.
Overall, the commercial assays have higher scores, both for
the Epstein–Barr virus tests and for the HCV tests. Also, the
commercial tests have a narrower range and fewer outlier
results.
(a) (b)
FIG. 1. (a) The scoring system for quantitative external quality assessment data. For each panel sample, a value is calculated and compared with
the consensus concentration. Scores are awarded from 0 (highly satisfactory, green) to 3 (highly unsatisfactory, orange to red) based on the dis-
tance from the calculated mean value for each panel sample. A score of 0 is awarded if the quantitative value returned is ±1 standard deviation
(SD) from the mean; a score of 1 is awarded if the quantitative value is ±2 SD; a score of 2 is awarded if the value is ±3 SD; and a score of 3 is
awarded if the value is >3 SD. (b) Comparative analysis of commercial vs. in-house tests. Note that the 2010 values are up until the month of
August. LOD/NR indicates that the average participant returned a limit of detection or no quantitative result.
(a)
(b)
FIG. 2. Comparative results for Epstein–Barr virus (EBV) (a) and hepatitis C virus (HCV) (b) obtained with both commercial and in-house-devel-
oped assays. From left to right, the viral titres in the samples increase, and it can be observed that in most, if not all, cases the in-house tests
underperform the commercial assays.
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What about the Performance of other
molecular Tests and Emerging Rapid Tests
or PoC Tests not belonging to Annex II
List A or B of EU Directive 98/79/EC?
Tests developed for Mycoplasma pneumoniae and Chlamydo-
phila pneumoniae were evaluated during the ﬁrst European
multicentre EQA for bacterial species [36,37]. QCMD devel-
oped a panel composed of 13 specimens, suspended in either
bronchoalveolar lavage ﬂuid or a simple transport medium.
Six specimens contained C. pneumoniae cells, with the num-
bers ranging from large to very small. Another ﬁve speci-
mens contained comparable numbers of M. pneumoniae cells.
Two negative control samples were included, and investiga-
tors were blinded to all samples. Seventy-nine laboratories in
18 countries participated in this EQA. The average percent-
age of correct results varied: only 54% of all participants
obtained correct results for the weakly positive M. pneumo-
niae samples, whereas these percentages increased to 90%
and >95% for the positive and strongly positive samples,
respectively. There were extensive differences among the
methods used in terms of nucleic acid extraction and ampliﬁ-
cation kits, and platform technologies. In general, laborato-
ries reportedly using the qualitative in-house PCRs
performed better than those using the commercially available
tests in terms of positive samples detected. In contrast, real-
time tests that were developed in house underperformed
signiﬁcantly as compared with commercial tests. The results
obtained for C. pneumoniae appeared to signiﬁcantly overlap
with the M. pneumoniae test outcomes.
Comparable studies were performed in the Framework
Programme 6-sponsored GRACE project (Genomics to
Combat Resistance Against Antibiotics in Community-
Acquired Lower Respiratory Tract Infections in Europe; EU
FP6 NoE: 03.2006–08.2011). The goal of GRACE was to
study the role of bacteria and viruses, including novel patho-
gens, in patients with community-acquired lower respiratory
tract infections in 3000 patients and 3000 controls. One of
the speciﬁc objectives of this study was to develop an EQA
panel containing the respiratory viruses and atypical bacterial
species, to evaluate the performance of different monoplex
and multiplex real-time nucleic acid ampliﬁcation tests (NA-
ATs) [38]. Table 1 shows a survey of some of the results of
such analyses, again for atypical pathogens. No false-negative
results were reported by laboratories 1 and 3, and labora-
tory 2 failed to detect three positive samples. The commer-
cially available RespiFinder plus assay (PathoFinder,
Maastricht, The Netherlands) failed to detect the sample
spiked with 18 CFU of Legionella pneumophila. All other
samples were correctly identiﬁed. The RespiFinder Smart 21
did not detect any of the samples spiked with L. pneumophila.
The manufacturer was contacted about this issue, and
improved the assay. The sensitivity of both Resplex assays
was very low; the original format (Resplex 1) yielded only
three positive samples; even after adaptation of the assay
(Resplex 2 assay), no improvement was seen; similar results
were obtained for some of the viruses. It is obvious that one
TABLE 1. Example of a multicentre assessment of the quality of a multiparametric viral detection assay. CCU; IFU; NTM
Sample no.
Sample
contenta
Concentration/
dilution (/ml)b
CT
c Resultd by:
Laboratory 1 Laboratory 2 Laboratory 3 ResPlex 1 ResPlex 2
RespiFinder
Plus SmartFinder 21
GRACE-35 M. pneumoniae 5000 CCU 29.15 36.3 28.44 M. pneumoniae Negative M. pneumoniae M. pneumoniae
GRACE-42 M. pneumoniae 500 CCU 32.6 39.1 31.78 Negative Negative M. pneumoniae M. pneumoniae
GRACE-48 M. pneumoniae 500 CCU 33.34 39.5 32.6 Negative Negative M. pneumoniae M. pneumoniae
GRACE-38 M. pneumoniae 50 CCU 34.49 Negative 36.85 Negative Negative M. pneumoniae M. pneumoniae
GRACE-37 L. pneumophila 1800 CFU 33.25;
M. pneumoniae 32.7
41.2;
M. pneumoniae 34.5
33.61;
M. pneumoniae
32.85
Negative Negative L. pneumophila,
M. pneumoniae
M. pneumoniae
GRACE-39 L. pneumophila 180 CFU 36.73 36.4 37.62;
M. pneumoniae
35.18
Negative Negative L. pneumophila Negative
GRACE-47 L. pneumophila 60 CFU 38.07;
M. pneumoniae 35.9
Negative 39.26 Negative Negative M. pneumoniae Negative
GRACE-45 L. pneumophila 18 CFU 40.08 Negative 40.85 Negative Negative Negative Negative
GRACE-43 C. pneumoniae 490 IFU 22.88 28.5 21.04 C. pneumoniae C. pneumoniae C. pneumoniae C. pneumoniae
GRACE-40 C. pneumoniae 49 IFU 26.27 31.2 24.17 C. pneumoniae C. pneumoniae C. pneumoniae C. pneumoniae
GRACE-44 C. pneumoniae 4.9 IFU 30.86 33.1 28.15 Negative Negative C. pneumoniae C. pneumoniae
GRACE-46 C. pneumoniae 4.9 IFU 29.91 34.8 27.69 Negative Negative C. pneumoniae C. pneumoniae
GRACE-36 NTM 0 Negative Negative Negative Negative Negative Negative Negative
GRACE-41 NTM 0 Negative Negative Negative Negative Negative Negative Negative
a NTM: negative transport medium
b CCU: color changing units; CFU: Colony forming Units; IFU: inclusion forming units
c Ct values indicate cycle threshold obtained with real-time PCRs
d Resplex 1, original Resplex format; resplex 2, primers and probes adapted by the manufacturer after obtaining the results of the Resplex 1 assay. The RespiFinder plus and
RespiFinder Smart 21 assays were from PathoFinder, Maastricht, the Netherlands; the Resplex assays were from Qiagen GmbH, Hilden, Germany
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of these commercial tests did not meet the quality require-
ments set by the combination of the other tests.
Pitfalls of Internet-accessible Diagnostic
Tests: (in)adequate Performance of a CE-
Marked Chlamydia test for Home use?
Several tests for microbiological diagnostics can be bought
‘over the counter’, and sometimes via convenient Internet
sources. The quality of such tests is not always obvious, and
comparative analyses may generate disappointing results. In
one study, a total of 231 women in two different clinics were
tested for C. trachomatis infection [39]. The evaluation con-
cerned the commercially accessible HandiLab-C Chlamydia
home test on vaginal swabs in comparison with the Roche Am-
plicor and Abbott m2000 nucleic acid tests. The concordance
between the two NAATs was very high, at 98.4%. On the
other hand, HandiLab-C showed a quite poor performance,
with sensitivities of 12.5% and 19.4% and speciﬁcities of 93.5%
and 88% vs. the two NAATs. Even worse, the overall positive
predictive value (PPV) and negative predictive value (NPV)
were in the order of 28% and 84.5%, respectively. Essentially,
HandiLab-C generated more false-positive than true-positive
results. Fifteen per cent of the women would assume that they
were uninfected, while actually being infected. Obviously, this
may have very serious public health consequences.
An important question is when poorly performing tests
are identiﬁed that pose potentially serious public health
issues, what action can be taken in order to prevent them
being available on the open market. It is obvious that the
continuing market availability of such poor testing systems
that are easily available from Internet sources could damage
the credibility of Internet sites that offer well-documented
and reliable testing systems. Educators and healthcare pro-
viders must inform at-risk population about assays that do
not provide reliable results [40]. Poor performance of CE-
marked tests should generate regulatory action to have this
CE mark removed from the market. International regulation
is needed to prevent sub-standard tests being obtained and
used. Currently, such regulatory systems are not in place.
Possible Reasons of Poor Performance of
CE-marked IVDs
There are two main reasons for poor test performance.
First, there may be major variations in performance that
depend on the test itself. The clinical sensitivity may be insuf-
ﬁcient, for a variety of reasons. Clearance of the test may
have been given after comparison with suboptimal reference
standard tests during the development phase. It has been
demonstrated that test performance can be negatively
affected, or at least inﬂuenced, by (extensive) multiplexing
(the simultaneous detection and enumeration of various
molecular targets in a single assay). There may also be prob-
lems with the clinical speciﬁcity, including primer/probe
design or natural changes, or the unexpected emergence of
pathogens. Such unexpected events require a full revalidation
of a pathogen-speciﬁc target or, in the worst case, of the
complete assay. Second, there may be clear variations in
end-user qualities that affect assay performance. For instance,
sample integrity, sampling technique and sample preparation
are all very important initial steps in high-quality testing
[41,42]. An important issue with sample processing is the
fact that samples are impure and large in volume, and, during
processing, nucleic acids need to be puriﬁed and concen-
trated in a limited number of steps, which is not simple.
Operator experience and training is another very important
diagnostic quality determinant. Finally, the inappropriate
interpretation of results and the absence or inferiority of
appropriate quality control may also be confounding factors.
Possibilities for Improvement in NAAT
Development and Monitoring
The text and examples above illustrate that, although guide-
lines for the appropriate development and use of molecular
tests do exist, their implementation is certainly not universal.
Major differences in test quality still exist, and, apparently,
the regulatory aspects do not prevent this from happening.
What can be done to improve this? Do we need additional
reﬁnement or changes in the Directive? Would it be helpful
for industry to join forces during development and quality
testing? We will use the Belgian approach to exemplify this.
This relates to the activities within the Belgian Institute of
Public Health related to IVD legislation. Within this initiative,
there is dedicated coordination and organization of pro-
grammes for external quality evaluation for the clinical labo-
ratories (RD 3-12-1999). Compliance with this programme
will lead to certiﬁcation of the laboratories for clinical biol-
ogy with activities in the framework of social security (RD 3-
12-1999). A competent authority for the in vitro medical
devices (KB 14-11-2001 and application of EU Directive 98/
79/EC) was thus established. This situation is unique in Eur-
ope, and in Belgium there is now a very short chain of deci-
sion-making. The practical activities of this body involve the
follow-up of performances of individual laboratories and the
IVDs that are currently in use. In case of deviations or upon
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the reporting of incidents, the legislative authorities seek
interaction with both clients and industry. This type of direct
interaction is quite successful, and has led to better informa-
tion of the competent authorities that are safeguarding
healthcare in association with test performances and docu-
mentation. IVD vigilance (RD 14-11-2001 and in combination
with EU Directive 98/79/EC) has increased the number of
notiﬁcations, has facilitated market surveillance, and, in the
end, may provide an optimal scenario for policy-making, also
at the level of the EU.
The Future of the IVD Directive
Between 8 May and 2 July 2008, the EU Commission services
consulted stakeholders on the revision of the legal frame-
work for medical devices [43]. Two hundred responses were
received from, among others, industry, healthcare profes-
sionals, academics, regulatory authorities, notiﬁed bodies,
patients, consumers, consultants, medical device experts,
standardization bodies, and health insurance and social secu-
rity providers. One message was that the majority of the
respondents prefer legal simpliﬁcation. The majority
expressed a clear preference for keeping the molecular diag-
nostics IVD devices in a separate category from other medi-
cal devices. There also seemed to be broad support from all
contributors for a revision of the IVD Directive. As a part of
a risk-based classiﬁcation, there was almost unanimous sup-
port for the classiﬁcation of IVD medical devices to be chan-
ged to a risk classiﬁcation (based on the Global
Harmonization Task Force guidance [44]), replacing the cur-
rent list system. The main goal of such a change would be to
improve the robustness of technological changes and to put
more emphasis on technological shortcomings and strengths
than on the medical risk of the target pathogens. Another
important issue that surfaced was the need for requirements
for evidence of clinical validity and/or utility. These items
were made public during a workshop for the EU Parliament
on 4 March 2009 [45]. The Global Harmonization Task
Force recently deﬁned a novel categorization (SG1/N045,
2008; Fig. 3 [44]). The importance here was to make clear
that, with increased risk during the performance of a test,
there would be a need for more precisely deﬁned and stric-
ter regulations.
The European Society of Clinical Microbiology and Infec-
tious Diseases reacted to the suggested revision of Direc-
tive 98/79/EC in September 2010. Again, adoption of a risk-
based classiﬁcation was considered to be an improvement.
It was suggested that, for all IVD tests except class A, pre-
market control of the manufacturer’s quality management
system had to be performed by an independent third party.
The control of each batch of manufactured high-risk
(class C and D) IVD tests had to be performed by the
manufacturers, but this should be complemented with ran-
dom checks by relevant authorities. For the so-called ‘in-
house tests’, the exemption provided by article 15 of the
Directive should be maintained, but with clariﬁcation. There
should be better deﬁnitions of ‘in-house test’ and all of its
afﬁliated jargon. Also, ‘essential requirements’ of the Direc-
tive should be fulﬁlled and evaluated by professional and
more formal accreditation bodies. Finally, it would be good
if the developers of in-house tests would submit details of
their manufacturing activities at the level of, for instance,
accreditation based on ISO 15189. With respect to PoC or
‘near-patient’ tests, the level of training and familiarity of
the user with the test procedures was deemed essential to
the validity of the test result. Hence, the European Society
of Clinical Microbiology and Infectious Diseases considered
it very important for the user to be informed of the value
(or lack of value) of the procedure, depending on the prev-
alence of the clinical conditions under study [46]. This was
to ensure that test speciﬁcations would meet the regional
requirement with respect to the sensitivity, speciﬁcity, NPV
and PPV of a test.
Integration between industrial and
Academic Test Development Activities
Can you imagine the challenges of shrinking a huge labora-
tory ﬁlled with people and equipment onto a single chip the
size of a matchbox? This is one of the developments fore-
seen in the ﬁeld of molecular testing. It is obvious that nei-
ther industry nor academia can achieve this single-handedly.
This combination of biological, biophysical and clinical activi-
ties would need an integrative approach requiring intensive
CLASS Risk level Device examples
A Low individual risk
and low public
health risk
Clinical chemistry analyser 
prepared selective culture media
B Moderate individual
risk and/or low
public health risk
Vitamin B12, Pregnancy self-testing, 
anti -nuclear antibody, urine test strips  
C High individual risk
and/or moderate
public health risk
Blood glucose self-testing, HLA typing, 
PSA screening, rubella
D High individual risk
and high public
health risk
HIV blood donor screening, HIV blood 
diagnostic
FIG. 3. Classiﬁcation scheme of in vitro diagnostic tests with respect
to the perceived risk levels of their targets. HIV, human immunodeﬁ-
ciency virus; PSA, prostate-speciﬁc antigen.
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collaboration between multidisciplinary teams of investigators
and developers. From a technological perspective, expertise
in, for instance, surface chemistry or photonics would be
required. The technologies of biosensing, sample processing
and protein chemistry would clearly require biotechnological
input [47].
Some Conclusions
The emerging technologies in the ﬁeld of medical diagnostics
of infectious diseases have the ability to decrease the time
required to obtain results from days to hours, and perhaps
even to minutes. This will permit improvement of the medi-
cal outcome for patients, and will revolutionize the ﬁeld of
infectious disease diagnostics. However, this will only be true
if the test result delivered is accurate and reliable. Hence,
IVD tests should only be used for the purpose intended by
the manufacturer, which implies that clear and unambiguous
instructions for use should be provided. Sensitivity, speciﬁc-
ity, PPV and NPV should be deﬁned during independent
studies, preferably carried out by experts in the ﬁeld. It must
be ensured that all staff members involved are appropriately
trained and are familiar with the instructions for use and the
interferences and limitations of the device or system. It is
recommended that IVD providers must participate in EQA
schemes to further validate the overall quality of their tests.
The importance of clinical utility should be stressed continu-
ously, and the inﬂuence of infectious agent prevalence on
predictive values should be underscored. And obviously,
cost-efﬁciency issues should be considered and monitored
very closely.
The quality of IVD tests should be reviewed on a continu-
ous basis, and a test should be withdrawn or suspended in
cases of deviations from the established and generally
accepted quality parameters. In cases of safety-related issues,
this should lead to batch recall and, in some cases, perhaps
even complete retraction [48–50].
Biotechnology companies and their clients and academia
should join forces in order to ensure that the above criteria
are independently reviewed and implemented from all differ-
ent perspectives. This can only be done adequately when
there is no communication gap between clinicians, biologists,
physicists, and chemists, and a strictly translational research
and development scheme would be ideal.
Clearly, molecular testing has evolved, and will continue
to evolve rapidly. Support systems, including regulatory activ-
ities, training for users, adequacy of the interpretation of
results, and communication on all test aspects, must evolve
at a similar pace.
Transparency Declaration
The authors have no conﬂicting interests within this work.
The authors thank Paul Wallace and Colin Steel for providing
the QCMD data and Figures.
References
1. Kwoh DY, Davis GR, Whitﬁeld KM, Chappelle HL, DiMichele LJ,
Gingeras TR. Transcription-based ampliﬁcation system and detection
of ampliﬁed human immunodeﬁciency virus type 1 with a bead-based
sandwich hybridization format. Proc Natl Acad Sci USA 1989; 86:
1173–1177.
2. Edelstein PH, Edelstein MA. Evaluation of the Meriﬂuor-Legionella
immunoﬂuorescent reagent for identifying and detecting 21 Legionella
species. J Clin Microbiol 1989; 27: 2455–2458.
3. Picken RN. Polymerase chain reaction primers and probes derived
from ﬂagellin gene sequences for speciﬁc detection of the agents of
Lyme disease and North American relapsing fever. J Clin Microbiol
1992; 30: 99–114.
4. Ohori H, Kanno A, Nagatsuka Y et al. An antigen/antibody system
speciﬁc for an epidemic non-A, non-B hepatitis in patients of a car-
diovascular surgical unit. J Med Virol 1983; 12: 161–178.
5. Rickard CM, McCann D, Munnings J, McGrail MR. Routine resite of
peripheral intravenous devices every 3 days did not reduce complica-
tions compared with clinically indicated resite: a randomised con-
trolled trial. BMC Med 2010; 8: 53.
6. Metcalfe TA. Development of novel IVD assays: a manufacturer’s per-
spective. Scand J Clin Lab Invest Suppl 2010; 242: 23–26.
7. Kayaba H. Rapid detection tests for viruses available in pediatric clin-
ics. Rinsho Byori 2002; 50: 1047–1054.
8. Sosnowski R, Heller MJ, Tu E, Forster AH, Radtkey R. Active micro-
electronic array system for DNA hybridization, genotyping and phar-
macogenomic applications. Psychiatr Genet 2002; 12: 181–192.
9. Brassard D, Clime L, Li K et al. 3D thermoplastic elastomer micro-
ﬂuidic devices for biological probe immobilization. Lab Chip 2011; 23:
4099–4107.
10. Zhao W, Brook MA, Yingfu L. Design of gold nanoparticle based col-
orimetric biosensing assays. ChemBioChem, 2008; 9: 2363–2371.
11. Bissonnette L, Bergeron MG. Next revolution in the molecular thera-
nostics of infectious diseases: micro-fabricated systems for personal-
ized medicine. Expert Rev Mol Diagn 2006; 6: 433–450.
12. Zhao W, Karp JM, Ferrari M, Serda R. Bioengineering nanotechnol-
ogy: towards the clinic. Nanotechnology 2011; 22: 490201.
13. Munson E, Kramme T, Culver A, Hryciuk JE, Schell RF. Cost-effective
modiﬁcation of a commercial PCR assay for detection of methicillin-
resistant or -susceptible Staphylococcus aureus in positive blood cul-
tures. J Clin Microbiol 2010; 48: 1408–1412.
14. http://www.ce-marking.org/directive-9879ec-IVD-MD.html.
15. Villars F, Pariente JL, Conort P. CE marking for medical devices. Prog
Urol 2005; 15: 985–991.
16. Donawa M. Medical device directive: preparing for the amendments.
Med Device Technol 2000; 11: 40–45.
17. Katawa G, Kpotsra A, Karou DS, Eklou M, Tayi KE, de Souza C.
Contribution to the establishment of quality assurance in ﬁve medical
microbiology departments in Togo. Bull Soc Pathol Exot 2011; 104:
20–24.
18. http://www.oecd.org/dataoecd/36/16/31724727.pdf.
19. Bremond J, Plebani M. IVD industry role for quality and accreditation
in medical laboratories. Clin Chim Acta 2001; 309: 167–171.
CMI Ieven et al. European quality clearance 37
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 29–38
20. Unemo M, Rossouw A, James V, Jenkins C. Can the Swedish new
variant of Chlamydia trachomatis (nvCT) be detected by UK NEQAS
participants from seventeen European countries and ﬁve additional
countries/regions in 2009? Euro Surveill 2009; 14: 19206.
21. Emmadi R, Boonyaratanakornkit JB, Selvarangan R et al. Molecular
methods and platforms for infectious diseases testing: a review of
FDA-approved and cleared assays. J Mol Diagn 2011; 13: 583–604.
22. Renub Research. Global molecular diagnostic market: opportunities and
future forecast. Rosewell, GA. 8/2009, RE-1503.
23. Nishino HT, Tambouret RH, Wilbur DC. Testing for human papillo-
mavirus in cervical cancer screening: a review of indications and
methodology. Cancer Cytopathol 2011; 119: 219–227.
24. Fredlund H, Falk L, Jurstrand M, Unemo M. Molecular genetic meth-
ods for diagnosis and characterisation of Chlamydia trachomatis and
Neisseria gonorrhoeae: impact on epidemiological surveillance and
interventions. APMIS 2004; 112: 771–784.
25. Cobb BR, Vaks JE, Do T, Vilchez RA. Evolution in the sensitivity of
quantitative HIV-1 viral load tests. J Clin Virol 2011; 52 (suppl): S77–
S82.
26. Jap A, Chee SP. Viral anterior uveitis. Curr Opin Ophthalmol 2011; 22:
483–488.
27. Endimiani A, Hujer KM, Hujer AM et al. Are we ready for novel
detection methods to treat respiratory pathogens in hospital-
acquired pneumonia? Clin Infect Dis 2011; 52 (suppl): S373–S383.
28. http://www.clsi.org/source/orders/free/MM19-P.pdf
29. Infectious Diseases Society of America. An unmet medical need: rapid
molecular diagnostics tests for respiratory tract infections. Clin Infect
Dis 2011; 52 (suppl): S384–S395.
30. Platts-Mills JA, Operario DJ, Houpt ER. Molecular diagnosis of diar-
rhea: current status and future potential. Curr Infect Dis Rep 2012; 14:
41–46.
31. de Pagter PJ, Schuurman R, de Vos NM, Mackay W, van Loon AM. Mul-
ticenter external quality assessment of molecular methods for detec-
tion of human herpesvirus 6. J Clin Microbiol 2010; 48: 2536–2540.
32. Pandit A, Mackay WG, Steel C, van Loon AM, Schuurman R. HIV-1
drug resistance genotyping quality assessment: results of the ENVA7
Genotyping Proﬁciency Programme. J Clin Virol 2008; 43: 401–406.
33. Mackay WG, van Loon AM, Niedrig M, Meijer A, Lina B, Niesters
HG. Molecular detection and typing of inﬂuenza viruses: are we
ready for an inﬂuenza pandemic? J Clin Virol 2008; 42: 194–197.
34. Barbi M, MacKay WG, Binda S, van Loon AM. External quality assess-
ment of cytomegalovirus DNA detection on dried blood spots. BMC
Microbiol 2008; 8: 2.
35. Staines HJ, Garcia-Fernandez L, Pogothata R, Wallace PS, MacKay
WG, Van Loon AM. Monitoring performance of nucleic acid based
diagnostic measurement system users by EQA. Accred Qual Assur
2009; 14: 243–252.
36. Loens K, Mackay WG, Scott C, Goossens H, Wallace P, Ieven
M. A multicenter pilot external quality assessment program to
assess the quality of molecular detection of Chlamydophila pneumo-
niae and Mycoplasma pneumoniae. J Microbiol Methods 2010; 82:
131–135.
37. Loens K, Beck T, Ursi D et al. Evaluation of different nucleic acid
ampliﬁcation techniques for the detection of M. pneumoniae, C. pneu-
moniae and Legionella spp. in respiratory specimens from patients with
community-acquired pneumonia. J Microbiol Methods 2008; 73: 257–
262.
38. Loens K, van Loon AM, Coenjaerts F et al. Performance of different
mono- and multiplex nucleic acid ampliﬁcation tests on a multipatho-
gen external quality assessment panel. J Clin Microbiol 2012; 50: 977–
987.
39. Michel CE, Saison FG, Joshi H, Mahilum-Tapay LM, Lee HH. Pitfalls of
internet-accessible diagnostic tests: inadequate performance of a CE-
marked Chlamydia test for home use. Sex Transm Infect 2009; 85:
187–189.
40. Gaydos CA. Can we climb out of the ‘pit’ of poorly performing rapid
diagnostic tests for chlamydia? Sex Transm Infect 2009; 85: 158.
41. Dannaoui E, Schwarz P, Slany M et al. Molecular detection and identi-
ﬁcation of zygomycetes species from parafﬁn-embedded tissues in a
murine model of disseminated zygomycosis: a collaborative European
Society of Clinical Microbiology and Infectious Diseases (ESCMID)
Fungal Infection Study Group (EFISG) evaluation. J Clin Microbiol 2010;
48: 2043–2046.
42. Sehgal A, Gupta S, Parashari A, Sodhani P, Singh V. Urine HPV-DNA
detection for cervical cancer screening: prospects and prejudices. J
Obstet Gynaecol 2009; 29: 583–589.
43. http://ec.europa.eu/health/medical-devices/documents/index_en.htm
44. http://www.ghtf.org/documents/sg1/sg1ﬁnal_n045.pdf
45. http://www.ghtf.org/steering/minutes/sc13-minutes.doc
46. http://www.docstoc.com/docs/81422902/Society-Assembly-of-Mem-
bers
47. Sı´pova´ H, Zhang S, Dudley AM, Galas D, Wang K, Homola J. Surface
plasmon resonance biosensor for rapid label-free detection of micro-
ribonucleic acid at sub-femtomole level. Anal Chem 2010; 82: 10110–
10115.
48. Raeymaekers M, Bakkus M, Boone E et al. Reﬂections and proposals
to assure quality in molecular diagnostics. Acta Clin Belg 2011; 66: 33–
41.
49. Weissfeld AS. Streamlined quality control of commercial microbial
identiﬁcation systems. Clin Microbiol Newslett 2011; 33: 35–37.
50. Grys TE. Developing a quality system for quantitative laboratory-
developed tests. Clin Microbiol Newslett 2011; 33: 179–185.
38 Clinical Microbiology and Infection, Volume 19 Number 1, January 2013 CMI
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 29–38
